ANRO vs APUS

Alto Neuroscience, Inc. vs Apimeds Pharmaceuticals US, Inc — Valuation Comparison 2026

ANRO

Pharmaceutical Preparations
Alto Neuroscience, Inc.
Quality
4.7
out of 10
Value Trap
12
SAFE
Price
$20.07
Last close
Models
7/13
Active
VS

APUS

Pharmaceutical Preparations
Apimeds Pharmaceuticals US, Inc
Quality
4.8
out of 10
Value Trap
6
SAFE
Price
$1.41
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType ANRO Fair ValueANRO Upside APUS Fair ValueAPUS Upside
Bayesian DCF Intrinsic $7.28 -63.7% $0.41 -70.8%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $1.91 -90.5% $6.62 +369.5%
Dynamic NAV Asset-Based $4.20 -79.1% $4.65 +230.1%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ANRO vs APUS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ANRO vs APUS — Which Stock Is More Undervalued?

APUS scores higher with a 4.8/10 quality rating vs ANRO's 4.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Alto Neuroscience, Inc. (ANRO) and Apimeds Pharmaceuticals US, Inc (APUS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ANRO currently trades at $20.07 with a QOC of 4.7/10, while APUS trades at $1.41 with a QOC of 4.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).